Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Healthcare Quarterly (Toronto, Ont.)|May 28, 2014
Evidence and quality, practicalities and judgments: some experience from NICEAnthony Culyer, Michael RawlinsInternational Journal of Technology Assessment in Health Care|July 5, 2022
Redefining Health Technology Assessment: A Comment on "The New Definition of Health Technology Assessment: A Milestone in International Collaboration"Anthony Culyer, Don HusereauF1000Research|June 16, 2018
Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays?Anthony Culyer, Kalipso Chalkidou, Yot Teerawattananon, et al.Health Affairs (Project Hope)|September 12, 2009
The NICE way of influencing health spending: a conversation with Sir Michael Rawlins. Interview by Nicholas TimminsMichael RawlinsHealth Economics|September 4, 2007
Cost-effective public health guidance: asking questions from the decision-maker's viewpointKalipso Chalkidou, Anthony Culyer, Bhash Naidoo, et al.Clinical Medicine (London, England)|January 20, 2009
De Testimonio: on the evidence for decisions about the use of therapeutic interventionsMichael RawlinsBulletin of the World Health Organization|January 7, 2020
Charging for the use of survey instruments on population health: the case of quality-adjusted life yearsYot Teerawattananon, Alia Cg Luz, Anthony Culyer, et al.Journal of Health Services Research & Policy|June 25, 2008
Evidence-informed evidence-makingKalipso Chalkidou, Tom Walley, Anthony Culyer, et al.Advances in Health Economics and Health Services Research|September 18, 2007
Can we model the impact of increased drug treatment expenditure on the U.K. drug market?Christine Godfrey, Steve Parrott, Gail Eaton, et al.Drug Discovery Today|September 10, 2011
Pharmacogenetics and cost-effectiveness analysis: a two-way streetKalipso Chalkidou, Michael RawlinsPageof 3